Ikonomidou Chrysanthy
Department of Pediatric Neurology, University Children's Hospital Carl Gustav Carus, University of Technology Dresden, Fetscherstrasse 74, 01307 Dresden, Germany.
Brain Dev. 2009 Aug;31(7):488-92. doi: 10.1016/j.braindev.2009.02.006.
Apoptosis occurs physiologically in the mammalian brain during the period of the growth spurt, which in human starts in the 3rd trimester of gestation and ends by the third year of life. Environmental factors can interact with programmed cell death mechanisms to increase the number of neurons undergoing apoptosis and thus produce neuropathological sequelae in the brain. In a series of studies it could be shown that classes of drugs which block N-methyl-D-aspartate (NMDA) glutamate receptors, promote gamma-aminobutyric-acid (GABA(A)) receptor activation or block voltage gated sodium channels, when administered to immature rodents during the period of the brain growth spurt, trigger widespread apoptotic neurodegeneration throughout the developing brain. Studies have also shown that short exposures to non-physiologic oxygen levels can trigger apoptotic neurodegeneration in the brains of infant rodents. Pathomechanisms involved in the proapoptotic action of sedative and anticonvulsant drugs and oxygen include decreased expression of neurotrophins, inactivation of survival signaling proteins, activation of inflammatory cytokines as well as oxidative stress. These findings raise concerns pertaining to the treatment of infants and young children with sedative and anticonvulsant drugs and premature infants with oxygen. The experimental findings imply that new approaches should be developed for patients within these vulnerable age groups.
细胞凋亡在哺乳动物大脑生长突增期会生理性发生,人类的这一时期始于妊娠晚期,止于三岁。环境因素可与程序性细胞死亡机制相互作用,增加发生凋亡的神经元数量,进而在大脑中产生神经病理后遗症。在一系列研究中发现,在大脑生长突增期给未成熟啮齿动物施用能阻断N-甲基-D-天冬氨酸(NMDA)谷氨酸受体、促进γ-氨基丁酸(GABA(A))受体激活或阻断电压门控钠通道的各类药物,会在整个发育中的大脑引发广泛的凋亡性神经变性。研究还表明,短期暴露于非生理性氧水平可在幼鼠大脑中引发凋亡性神经变性。镇静和抗惊厥药物以及氧气促凋亡作用涉及的病理机制包括神经营养因子表达降低、生存信号蛋白失活、炎性细胞因子激活以及氧化应激。这些发现引发了对使用镇静和抗惊厥药物治疗婴幼儿以及给早产儿输氧的担忧。实验结果表明,应为这些脆弱年龄组的患者开发新的治疗方法。